
Please try another search
As the world eagerly awaits results for the U.S. Presidential election, there's yet another highly anticipated event: a breakthrough in the coronavirus vaccine.
Positive news about an approved vaccine for SARS-CoV-2, the virus behind the pandemic, could make a big difference not only for daily lives worldwide but also for many stocks.
We've addressed some of the companies and exchange-traded funds (ETFs) appropriate for those looking to bet on biopharma stocks.
Below we take a closer look at companies leading the race for the vaccine and an ETF to help investors gain broader exposure:
Globally, there have been over 46 million confirmed COVID-19 cases.
The World Health Organization (WHO) publishes updates on worldwide scientific work on a potential cure for the novel coronavirus. Three of the biopharma companies attracting attention in recent weeks from that list include Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX), and Moderna (NASDAQ:MRNA).
In an open letter of Oct. 16, Pfizer's CEO, Dr. Albert Bourla, underlined three big issues in the development of a successful vaccine:
Pfizer and Germany-based partner BioNTech are about to receive efficacy results from the late-stage trial of the vaccine. According to Dr. Bourla:
"Assuming positive data, Pfizer will apply for Emergency Authorization Use in the U.S. soon after the safety milestone is achieved in the third week of November."
BioNTech went into detail on its manufacturing plans, saying "if regulatory authorization or approval is obtained, [we] expect to manufacture up to 100 million doses by the end of 2020 and potentially more than 1.3 billion doses by the end of 2021."
Moderna, also shared some promising updates when it released Q3 financial results Oct. 29, saying it recently "completed enrolment of 30,000 participants for the Phase 3 COVE study of mRNA-1273, its vaccine candidate against COVID-19."
In the third-quarter report, management said:
"We are actively preparing for the launch of mRNA-1273 and we have signed a number of supply agreements with governments around the world."
The scientific community, as well as investors, are waiting for further updates, each of which influences relevant stock prices. Since the start of the year, MRNA shares are up over 240%.
Investing in the sector via an ETF provides exposure to the gains from vaccine development without needing to monitor the fast-paced scientific developments of each company.
Here's one to consider:
The ETFMG Treatments, Testing and Advancements ETF (NYSE:GERM) is made up of biopharma businesses that are developing vaccines or other cures as well as diagnostic technology against infectious diseases.
The fund started trading in June 2020. Although most investors would understandably regard the COVID-19 as the primary focus, there are over 20 epidemic diseases countries are working against.
Thus, the work done by these firms or other newcomers will not end even if there is a vaccine against the novel coronavirus soon. According to a report by MarketsandMarkets, "The global vaccines market is projected to reach USD 58.4 billion by 2024 from USD 41.7 billion in 2019, at a CAGR of 7.0% during the forecast period."
GERM, which has 63 holdings, follows the Prime Treatments, Testing and Advancements Index. The top ten businesses make up about 45% of the fund's net assets of over $50 million.
BioNTech, Moderna, diagnostic test manufacturer Quidel (NASDAQ:QDEL), drug treatment developer Hercules (NYSE:HTGC), life science research and clinical diagnostics firm Bio-Rad Laboratories (NYSE:BIO) and diagnostic information services provider Quest Diagnostics (NYSE:DGX) head the list of firms.
Also, shares of other companies working on a COVID-19 cure are included in GERM. CureVac (NASDAQ:CVAC), Gilead (NASDAQ:GILD), Ibio (NYSE:IBIO), Inovio Pharmaceuticals (NASDAQ:INO), Merck (NYSE:MRK), Novavax (NASDAQ:NVAX), Regeneron Pharmaceuticals (NASDAQ:REGN), Sanofi (NASDAQ:SNY) and Sorrento Therapeutics (NASDAQ:SRNE) are a few such companies among others.
Since its inception, the fund is up over 7% and hit a high of $35.15 on July 20. GERM's short-term fortunes are likely to ebb and flow with vaccine news headlines, especially on the final stages of clinical trials and potential approvals by national authorities.
A successful vaccine in the coming weeks could significantly influence the global economy and lift hope for 2021. Biotech ETFs, in particular, could profit from a successful vaccine.
Those market participants considering allocating some of their investment capital to biopharma in hopes of a vaccine soon could also research the following ETFs:
Fears of a possible US recession have been growing among Wall Street’s analysts, helping push the S&P 500 index to the verge of an official bear market. As investors...
Investors were net redeemers of mutual fund and ETF assets for the Refinitiv Lipper fund-flows week ended Wednesday, May 18, 2022, collectively handing back a net $30.9...
With surging inflation, many consumers have been feeling the pinch of rising food prices lately. But here’s an excellent way to profit from the situation through buying an...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.